Bayer, Japanese university partner for Alzheimer's research

09/11/2008 | PipelineReview.com

Bayer Schering Pharma and the University of Nagasaki in Japan have signed a licensing agreement for the use of novel molecular imaging agents developed there as PET radiotracers to help in the early detection of Alzheimer's disease. The agreement grants Bayer exclusive worldwide rights to manufacture and sell a set of radiolabeled molecules.

View Full Article in:

PipelineReview.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD